- $983.84m
- $862.70m
- 41
- 15
- 55
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.16 | ||
| Price to Tang. Book | 7.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -77.08% | ||
| Return on Equity | -53.27% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 150 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Directors
- Remi Barbier CHM (61)
- Eric Schoen CFO (52)
- Nadav Friedmann OTH (78)
- James Kupiec OTH (68)
- Richard Barry IND (42)
- Robert Gussin IND (83)
- Michael O' Donnell IND (62)
- Sanford Robertson IND (89)
- Patrick Scannon IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 4th, 1998
- Public Since
- July 14th, 2000
- No. of Shareholders
- 28
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 43,245,758
- Address
- 6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, 78731
- Web
- https://www.cassavasciences.com/
- Phone
- +1 5125012444
- Auditors
- Ernst & Young LLP
Upcoming Events for SAVA
Cassava Sciences Inc Annual Shareholders Meeting
Cassava Sciences Inc Annual Shareholders Meeting
Q2 2024 Cassava Sciences Inc Earnings Release
Similar to SAVA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Cassava Sciences share price?
As of Today at 19:05 UTC, shares in Cassava Sciences are trading at $22.75. This share price information is delayed by 15 minutes.
How has the Cassava Sciences share price performed this year?
Shares in Cassava Sciences last closed at $22.75 and the price had moved by -3.68% over the past 365 days. In terms of relative price strength the Cassava Sciences share price has underperformed the S&P500 Index by -22.22% over the past year.
What are the analyst and broker recommendations for Cassava Sciences?
The overall consensus recommendation for Cassava Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cassava Sciences dividend yield?
Cassava Sciences does not currently pay a dividend.
Does Cassava Sciences pay a dividend?
Cassava Sciences does not currently pay a dividend.
When does Cassava Sciences next pay dividends?
Cassava Sciences does not currently pay a dividend.
How do I buy Cassava Sciences shares?
To buy shares in Cassava Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cassava Sciences?
As of the previous close price of $22.75, shares in Cassava Sciences had a market capitalisation of $983.84m.
Where are Cassava Sciences shares listed?
Here are the trading details for Cassava Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SAVA
What kind of share is Cassava Sciences?
Based on an overall assessment of its quality, value and momentum Cassava Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cassava Sciences share price forecast for 2024?
The analyst consensus target price for shares in Cassava Sciences is $99.50. That is 337.36% above the last closing price of $22.75.
Analysts covering Cassava Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.15 for the next financial year.
What is the trend in the Cassava Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cassava Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +30.69%.
As of the last closing price of $22.75, shares in Cassava Sciences were trading +6.27% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cassava Sciences PE Ratio?
The Cassava Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $22.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cassava Sciences?
Cassava Sciences' management team is headed by:
- Remi Barbier - CHM
- Eric Schoen - CFO
- Nadav Friedmann - OTH
- James Kupiec - OTH
- Richard Barry - IND
- Robert Gussin - IND
- Michael O' Donnell - IND
- Sanford Robertson - IND
- Patrick Scannon - IND